IMab Approved to Start China Trials of Interleukin7 Immunotherapy

I-Mab Approved to Start China Trials of Interleukin-7 Immunotherapy

I-Mab Biopharma of  Shanghai reported the China National Medical Products Administration approved its IND for TJ107 (HyLeukin®), a novel long-acting recombinant human interleukin-7 (rhIL-7). I-Mab in-licensed China rights to the immunotherapy in a $548 million agreement late last year from South Korea's Genexine. To create the long-term effect, Genexine fuses Interleukin-7 with its own hybrid Fc platform. I-Mab will test HyLeukin in patients with chemotherapy-induced lymphopenia and cancer. More details....

Stock Symbol: (KOSDAQ: 095700)

Share this with colleagues:

Original Article: I-Mab Approved to Start China Trials of Interleukin-7 Immunotherapy

More From BioPortfolio on "I-Mab Approved to Start China Trials of Interleukin-7 Immunotherapy"